Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 4/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.37 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828304 | 1.00 | NT5E (0.40) | NT5ETGM2KRASTAAR1HPGD | |
| SCHEMBL15828297 | 0.86 | NT5E (0.47) | NT5ETGM2KRASTAAR1HINT1 | |
| SCHEMBL15828302 | 0.86 | NT5E (0.47) | NT5ETGM2KRASTAAR1HINT1 | |
| SCHEMBL15828245 | 0.83 | TAAR1 (0.41) | NT5ETGM2KRASTAAR1HPGD | |
| SCHEMBL15588481 | 0.80 | ADORA3 (0.47) | NT5ETAAR1HPGDSTING1HINT1 | |
| SCHEMBL22236552 | 0.80 | ADORA3 (0.47) | NT5ETAAR1HPGDSTING1HINT1 | |
| SCHEMBL15588765 | 0.78 | TAAR1 (0.40) | NT5ETGM2KRASTAAR1HPGD | |
| SCHEMBL22392931 | 0.70 | P2RX1 (0.57) | TAS1R3TAS1R1PDE3A | |
| SCHEMBL26361760 | 0.70 | P2RX1 (0.57) | TAS1R3TAS1R1PDE3A | |
| SCHEMBL26937515 | 0.70 | P2RX1 (0.57) | TAS1R3TAS1R1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211300-B2 | 4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | FBL, HNRNPLL, SLC28A1 | NT5E 392/4885TGM2 2874/4885KRAS 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.